A Study for Adults With Recurrent IDH1 or IDH2 Mutated Gliomas
National Cancer Institute researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.
What the Study Involves
- Full physical and neurological examination
- Health and symptoms questionnaire
- MRIs and laboratory tests
- Study of tumor tissue from prior surgeries
- Receive drug nivolumab for up to 20 treatments over 64 weeks
- Your samples used for genetic and biomarker testing
- Monitoring calls every six months after treatment
- Visits every month during treatment and 28, 60, 100 days after treatment
- All tests, procedures and medications provided at no cost
You Can Participate if You
- Are age 18 or older
- Are diagnosed with a glioma with IDH1or IDH2 mutation that has returned
- Do not have hepatitis
- Are not pregnant or breastfeeding
The NIH Clinical Center, America's Research Hospital located in Bethesda, MD, Metro red line (Medical Center stop).
For More Information
NIH Clinical Center
Office of Patient Recruitment
800-411-1222
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov
Or go online
Refer to study 19-C-0006
Department of Health and Human Services
National Institutes of Health Clinical Center
National Cancer Institute